Research Group Purpose and Strategy

To promote quality and generate new knowledge in clinical neonatal medicine. The primary strategy is to utilize prospectively collected, quality-controlled registry data for this purpose, as well as to initiate and participate in clinical studies.

Homepage at UiO (med.uio.no)

• TREOCAPA – European clinical randomized placebo-controlled study on prophylactic treatment of ductus arteriosus in premature infants born before 29 weeks of gestation.
• Early and late sepsis in a national cohort of premature babies born before 32 weeks of pregnancy during the years 2009 to 2019
• Risk factors for early and late sepsis in a national cohort of premature babies born before 32 weeks during the years 2009 to 2019
• Gram-negative sepsis in a national cohort of premature babies born before 32 weeks during the years 2009 to 2014, virulence factors and antibiotic resistance
• Risks associated with long-term antibiotics exposure without a recognized agent, based on data from NNK (Norwegian Neonatal Network database)
• Consequences of survival and morbidity in the neonatal period for 5 to 10-year old children treated with therapeutic hypothermia during the years 2009 to 2016
• Risk factors for perinatal asphyxia and therapeutic hypothermia during pregnancy and birth in the years 2009 to 2016
• Neonatal seizures; risk factors during pregnancy and birth
• Stillbirths and death during the first year of life – a 10-year long cohort study from 2009 to 2018
• Factors predicting weaning success in extremely premature infants born before 26 weeks of gestation
• Fetal assessment of the myocardium and evaluation of the neonate (FAME-n) study
• CRIB II score as a predictor of morbidity and mortality in premature infants born before 32 weeks of gestation, using data from the Norwegian Neonatal Network database